References
- Hendrickson R. Chapter 35: Acetaminophen. In: Hoffmann RS, et al. Goldfrank’s toxicologic emergencies. 10th ed. New York, NY: McGraw-Hill; 2015. p. 447–464.
- Ryder SD, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease. BMJ. 2001;322(7281):290–292.
- Tittarelli R, Pellegrini R, Scarpellini MG, Marinelli E, Bruti V, di Luca NM, Busardò FP, Zaami S. Hepatotoxicity of paracetamol and related fatalities. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):95–101.
- Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, Lee WM Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372.
- O’Malley GF, Mizrahi F, Giraldo P, O'Malley RN, Rollins D, Wilkins D. Protein-derived acetaminophen-cysteine can be detected after repeated supratherapeutic ingestion of acetaminophen in the absence of hepatotoxicity. J Med Toxicol. 2015;11:317–320.
- Eakins R, Walsh J, Randle L, Jenkins RE, Schuppe-Koistinen I, Rowe C, Starkey Lewis P, Vasieva O, Prats N, Brillant N, Auli M, Bayliss M, Webb S, Rees JA, Kitteringham NR, Goldring CE, Park BK. Adaptation to acetaminophen exposure elicits major changes in the expression and distribution of the hepatic proteome. Sci Rep. 2015;5:16423.
- Heard KJ, Green JL, James LP, et al. Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. BMC Gastroenterol. 2011;11:20.
- Heard K, Green JL, Anderson V, et al. Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. Br J Clin Pharmacol. 2016;81(3):562–568.
- Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X, Black M. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999;29(2):451–463.